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BACKGROUND Results of studies in experimental animals have shown that, with age, myocardial fatty acid
metabolism decreases, and glucose metabolism increases. Whether similar changes occur in
humans is unknown.
METHODS Seventeen healthy younger normal volunteers (six males, 26  5 years) and 19 healthy older
volunteers (nine males, 67  5 years) underwent positron emission tomography (PET) under
resting conditions in the fasted state. Myocardial blood flow (MBF), myocardial oxygen
consumption (MVO2), myocardial fatty acid utilization (MFAU) and oxidation (MFAO),
and myocardial glucose utilization (MGU) were quantified by PET with 15O-water,
11C-acetate, 11C-palmitate, and 11C-glucose, respectively.
RESULTS Although MBF was similar between the groups, MVO2 was higher in the older subjects (5.6
 1.6 mol/g/min) compared with younger subjects (4.6  1.0 mol/g/min, p  0.04).
Rates of MFAU and MFAO (corrected for MVO2) were significantly lower in older subjects
than in younger subjects (MFAU/MVO2: 35  10 vs. 51  20 nmol free fatty acids
(FFA)/nmol O2  10
3, p  0.005, and MFAO/MVO2: 33  10 vs. 48  18 nmol
FFA/nmol O2  10
3, p  0.004). In contrast, the rates of MGU corrected for MVO2 did
not differ between the groups.
CONCLUSIONS With aging, humans exhibit a decline in MFAU and MFAO. Although absolute rates of
MGU do not increase, by virtue of the decline in MFAU there is likely an increase in relative
contribution of MGU to substrate metabolism. The clinical significance of this metabolic
switch awaits further study. (J Am Coll Cardiol 2003;41:293–9) © 2003 by the American
College of Cardiology Foundation
Cardiovascular disease is a primary cause of disability and
death in Americans 65 years of age or older (1,2). Aging is
associated with a variety of cardiac abnormalities. For
example, there is an age-related decline in myocardial
vasodilator capacity (3,4). Although ventricular systolic
function at rest is preserved, both left ventricular systolic
reserve capacity and diastolic filling decline with age (5). In
addition to these normal aging effects on myocardial perfu-
sion and function, both the incidence and clinical manifes-
tations of a variety of cardiac disorders such as dilated
cardiomyopathy, hypertension-induced left ventricular hy-
pertrophy, and cardiomyopathy associated with diabetes
mellitus increase with age (5–7). Numerous mechanisms,
such as tissue oxygen free-radicals and reduced -adrenergic
sensitivity, have been proposed for being at least partially
responsible for these age-related effects on the heart (8–10).
However, alterations in the pattern of myocardial sub-
strate use may play a key role as well. Based on results of
studies in experimental animals, the pattern of myocardial
substrate metabolism varies with advancing age. In the
mature heart, fatty acids are the preferred energy source
(11,12). With senescence, there is a decline in fatty acid
metabolism, and the proportion of glucose metabolism to
overall substrate metabolism increases (13,14). Whether
similar age-related changes in myocardial substrate metab-
olism occur in humans is unknown. Accordingly, the
purpose of the current study was to determine if there is an
age-related shift in myocardial substrate metabolism in
healthy older humans.
METHODS
Study population. Seventeen young, sedentary, healthy
subjects (six men; mean age, 26  5 years) and 19 older,
sedentary, healthy subjects (nine men; mean age, 67  5
years) were studied. Sedentary subjects were chosen to
minimize the confounding effects of variable levels in
training-induced adaptations of myocardial substrate me-
tabolism. All subjects were nonsmokers, normotensive, and
were without a family history for coronary artery disease.
Occult diabetes was excluded by an oral glucose tolerance
test, although two of the older subjects had evidence of
borderline glucose intolerance. Hyperlipidemia was ex-
cluded by a normal plasma lipid profile. None of the subjects
had any other systemic illness. No subjects were taking any
medications at the time of the study. Subclinical coronary
artery disease and other forms of cardiac disease were
excluded by a normal physical exam and a normal rest/
exercise echocardiogram. Normal left ventricular systolic
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function at rest was confirmed by demonstration of a normal
left ventricular ejection fraction in both the younger (65 
7%) and older subjects (68 5%, pNS) quantified on the
echocardiograms. Left ventricular hypertrophy was excluded
by confirming with echocardiography a normal left ventric-
ular mass index in both the younger (79 9 g/m2) and older
(76  10 g/m2, p  NS) groups. The study was approved
by the Human Studies and the Radioactive Drug Research
Committees at the Washington University School of Med-
icine. Written informed consent was obtained from all
subjects before enrollment into the study.
Imaging protocol. All studies were performed on a con-
ventional commercially available tomograph (Siemens
ECAT 962 HR, Siemens Medical Systems, Iselin, New
Jersey). All subjects were studied after an overnight fast
under resting conditions. They were placed on telemetry
and had blood pressures obtained routinely throughout the
study. Positron emission tomography (PET) was used to
measure myocardial blood flow (MBF) with 15O-water,
myocardial oxygen consumption (MVO2) with
11C-acetate,
myocardial fatty acid utilization (MFAU) and oxidation
(MFAO) with 11C-palmitate, and myocardial glucose uti-
lization (MGU) with 11C-glucose. During the study, ve-
nous blood samples were obtained at predetermined inter-
vals to measure plasma substrate (glucose, fatty acids, and
lactate) and insulin levels. In addition, plasma levels of
11CO2 values and
11C-lactate were measured to correct the
arterial input function during compartmental modeling of
the myocardial kinetics of the various metabolic tracers (see
the following text).
Image analysis. Myocardial 15O-water, 11C-acetate, 11C-
glucose, and 11C-palmitate images were generated and then
reoriented to standard short- and long-axis views. To
generate myocardial time-activity curves, regions of interest
encompassing the anterior-lateral wall (3 to 5 cm3) were
placed on three to four midventricular short-axis slices of
composite 15O-water, 11C-acetate, 11C-glucose, and 11C-
palmitate images as previously described (15). To generate
blood time-activity curves for each tracer, a small region of
interest (1 cm3) was placed within the left atrial cavity on a
midventricular slice in the horizontal long-axis orientation
of each composite image. Within these regions of interest,
myocardial and blood time-activity curves were generated
for each of the tracer data sets. Subsequently, blood and
myocardial time-activity curves were used in conjunction
with well-established kinetic models to measure MBF,
MVO2, MFAU, and MFAO in each myocardial region
analyzed and averaged to obtain one value for MBF,
MVO2, MFAU, and MFAO per subject.
MEASUREMENT OF MBF. By applying the image-analysis
routine to the time-segmented data, myocardial time-
activity curves for each segment were generated. From these
data, MBF was quantified in ml/g/min using a previously
validated compartmental modeling method (16,17).
MEASUREMENT OF MVO2, MGU, MFAU, AND MFAO. To mea-
sure 11CO2 and
11C-lactate plasma levels, total 11C-acidic
metabolites (11C-lactate and 11CO2) were first separated
from neutral sugars by trapping them in an ion exchange
column (AG1-X4 resin 100 to 200 mesh, formate form).
The plasma sample was then eluted through this column
with 5 ml of water. Both resin and eluate were counted for
radioactivity to obtain the total acidic metabolites and
nonmetabolized glucose present. A similar serum sample
was also deposited in a test tube, acidified with 6N HCl,
sparred with N2 for 10 min to eliminate the
11CO2, and
counted for radioactivity against a sample kept under basic
conditions. The count difference between the test tubes was
used to calculate the %11CO2 present in the plasma sample.
To obtain the %11C-lactate, the %11CO2 was subtracted
from the total percent of acidic metabolites present in the
resin. After correcting PET-derived blood activity for the
11CO2 contribution, blood and myocardial time-activity
curves were used in conjunction with a one-compartment
kinetic model to estimate the rate at which 11C-acetate is
converted to 11CO2 (k2, min
1) (18,19). Values for MVO2
in mol/g/min were then determined using a previously
published relationship between k2 and MVO2 (19). After
correcting PET-derived blood activity for 11CO2 and
11C-
lactate, blood and myocardial 11C-glucose time-activity
curves were analyzed with a four-compartment kinetic
model to measure fractional myocardial glucose extraction
(15). In a similar fashion, after correcting PET-derived
blood activity for 11CO2, blood and myocardial
11C-
palmitate time-activity curves were analyzed with a four-
compartment kinetic model to measure fractional myocar-
dial palmitate extraction and oxidation (20). These
extraction fractions were then used in conjunction with
MBF and plasma levels of glucose or free fatty acid to
calculate MGU, MFAU, and MFAO (nmol/g/min).
Measurements of plasma insulin and substrates. Plasma
insulin levels were measured by radioimunoassay (21).
Plasma glucose and lactate levels were measured using a
commercially available glucose-lactate analyzer (YSI, Yel-
low Springs, Ohio). The level of fatty acids in plasma was
determined by capillary Gas Chromatography and HPLC
(15,20).
Statistical analysis. Individual parameter values were aver-
aged and expressed as the mean values  the SD. Compar-
isons between groups were performed by unpaired t test; p
values  0.05 were considered statistically significant.
Abbreviations and Acronyms
FFA  free fatty acids
GLUT-4  glucose transporter isoform 4
MBF  myocardial blood flow
MFAO  myocardial fatty acid oxidation
MFAU  myocardial fatty acid utilization
MGU  myocardial glucose utilization
MVO2  myocardial oxygen consumption
PET  positron emission tomography
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RESULTS
Plasma substrates and insulin. Shown in Table 1 are the
plasma glucose, fatty acid, lactate, and insulin levels aver-
aged for the entire imaging study for the two groups. Plasma
glucose and fatty acid levels did not differ between older and
younger subjects. However, plasma lactate levels were sig-
nificantly higher in the older individuals compared with
younger subjects (p  0.03). Plasma insulin levels did not
differ between the two groups. There were no significant
differences in the level of plasma substrates or insulin during
the various imaging portions of the study in the younger or
the older subjects. Moreover, the percent of variability in
these levels did not differ between the two groups.
Hemodynamics. Heart rate did not differ between the
groups (Table 2). However, both systolic blood pressure (p
 0.001) and diastolic blood pressure (p  0.05) were
higher in the older subjects compared with younger indi-
viduals. As a consequence, the rate-pressure product tended
to be higher in the older group (Table 2, p  0.1). There
were no differences in the hemodynamic levels during the
15O-water, 11C-acetate, 11C-glucose, and 11C-palmitate
PET studies for either group.
MBF and MVO2. Shown in Figure 1 are the average
values and SDs for the levels of MBF and MVO2 for the
two groups. Values for MBF were similar for younger and
older subjects averaging 1.0  0.2 ml/g/min and 1.1  0.3
ml/g/min, respectively, p  NS. In contrast, MVO2 was
significantly higher in the older group averaging 5.6  1.6
mol/g/min compared with the younger group where
MVO2 averaged 4.6  1.0 mol/g/min, p  0.05, paral-
leling the higher systolic and diastolic blood pressures in the
older subjects.
MFAU, MFAO, and MGU. Shown in Figure 2 are the
average values for MFAU, MFAO, and MGU without
correction for MVO2 for the two groups. Values for MFAU
did not differ between older subjects (224  71 nmol/g/
min) and younger subjects (198  72 nmol/g/min, p 
NS). Moreover, differences did not exist in the oxidation of
extracted fatty acid as evidenced by comparable MFAO
values between older subjects (183  72 nmol/g/min) and
younger subjects (209  55 nmol/g/min, p  NS). In
contrast, values for MGU were significantly higher in older
subjects averaging 215  125 nmol/g/min when compared
with younger subjects where values averaged 144  76
nmol/g/min, p  0.05.
Increases in myocardial workload can cause a preferential
increase in MGU relative to MFAU and MFAO (22).
Because the systolic and diastolic blood pressures were
higher in the older subjects compared with younger subjects,
values for substrate utilization were also corrected for
MVO2 in order to normalize for differences in workload
between the two groups (Fig. 3). When this correction was
made, the level of MFAU was significantly lower in older
subjects (35  10 nmol free fatty acids (FFA)/nmol O2 
103 compared with younger subjects (51  19 nmol
FFA/nmol O2  10
3, p  0.005). This decrease in
myocardial fatty acid utilization was paralleled by a decrease
in fatty acid oxidation as evidenced by MFAO/MVO2
values of 33  10 nmol FFA/nmol O2  10
3 in the older
group compared with values of 48  18 nmol FFA/nmol










Younger (n  17) 64  9 111  12 64  7 5,087  1,050
Older (n  19) 63  8 130  19* 71  10† 5,792  1,317
Values represent mean  SD for measurements obtained throughout the PET study.
*p  0.001; †p  0.05.
DBP  diastolic blood pressure; HR  heart rate; PET  positron emission
tomography; RPP rate pressure product [(SBP 2 DBP)/3) HR]; SBP systolic
blood pressure.
Figure 1. Average values and standard deviations for the levels of myocardial blood flow (MBF) and oxygen consumption (MVO2) for the younger and
older subjects. Although MBF was similar between the groups, MVO2 was higher in the older subjects compared with the younger subjects. *p  0.05.
Open bar  younger subjects; solid bar  older subjects.










Younger (n  17) 4.8  0.3 0.67  0.22 0.68  0.18 5.9  2.5
Older (n  19) 5.1  0.5 0.60  0.15 0.92  0.30* 4.5  1.7
Values represent mean  SD for measurements obtained throughout the PET study.
*p  0.001.
PET  positron emission tomography.
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O2  10
3 in the younger group (p  0.004). However,
correction for MVO2 resulted in the disappearance in the
difference in levels of MGU between older and younger
subjects (43  30 nmol glucose/nmol O2  10
3 and 35 
24 nmol glucose/nmol O2  10
3, respectively, p  NS).
MFAU, MFAO, and MGU—impact of plasma lactate
levels. Increases in plasma lactate levels have been reported
to decrease MFAU and MFAO in experimental animals
(11,12). To determine if the higher plasma lactate levels
contributed to the switch in substrate metabolism in the
older subjects, we correlated values for MFAU/MVO2,
MFAO/MVO2, and MGU/MVO2 with plasma lactate
levels in the younger and older subjects (Fig. 4). No
relationship was noted between the plasma lactate levels and
the measurements of myocardial fatty acid and glucose
metabolism.
DISCUSSION
The results of this study are the first to demonstrate that in
healthy humans with normal resting systolic function there
is an age-related shift in myocardial substrate metabolism.
This shift is manifested as an absolute decline in MFAU
and MFAO without a change in MGU. As a consequence,
the relative contribution of the MFAU and MFAO to
overall substrate metabolism is decreased, and the relative
contribution of MGU is likely increased.
Myocardial metabolism and age. In the normal adult
myocardium, mitochondrial -oxidation of fatty acids is the
primary source of energy production in the fasted state
(11,12). In both mouse and rat experimental models of
aging, the contribution of MFAO to overall myocardial
substrate metabolism declines with age (13,14). It appears
the decrease in MFAO is secondary to an age-related
decline in carnitine palmitoyltransferase-1 activity, the rate-
limiting enzyme for mitochondrial long-chain fatty acid
uptake (23). Our results confirm that this age-related
decline in MFAO also occurs in the normal human heart.
Because both MFAU and MFAO decreased with age, we
are unable to determine whether the decline in MFAO was
the primary site of the age-related effect on myocardial fatty
acid metabolism or if it was secondary to other abnormali-
ties in fatty acid handling by the myocardium such as
decreased fatty acid transport across the sarcolemma.
The effects of aging on myocardial glucose metabolism
are less clear. In various mouse models of aging, there is an
increase in the myocardial protein content for the glucose
Figure 2. Average values and standard deviations for the levels of myocardial fatty acid utilization (MFAU) and oxidation (MFAO) and myocardial glucose
utilization (MGU). The MFAU and MFAO did not differ between the groups, whereas MGU was higher in the older group compared with the younger
group. *p  0.05. Open bar  younger group; solid bar  older group.
Figure 3. Values for myocardial fatty acid utilization (MFAU) and oxidation (MFAO) and myocardial glucose utilization (MGU) all corrected for
myocardial oxygen consumption (MVO2). Both MFAU/MVO2 and MFAO/MVO2 were lower in the older subjects compared with younger subjects. The
MGU/MVO2 did not differ between the groups. FFA free fatty acids. *p 0.005; **p 0.004. Open bar younger subjects; solid bar older subjects.
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Figure 4. Correlation between plasma lactate levels and values for myocardial fatty acid utilization (MFAU) and oxidation (MFAO) and myocardial glucose
utilization (MGU) all corrected for myocardial oxygen consumption (MVO2) in both younger and older subjects. There was no relationship between the
plasma lactate level and MFAU/MVO2 (A), MFAO/MVO2 (B), MGU/MVO2 (C).
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transporter isoform 4 (GLUT-4) suggesting an increase in
myocardial glucose uptake (24–26). However, in the rat,
myocardial GLUT-4 content decreases with age (27). Yet,
glucose metabolism relative to fatty acid metabolism is
proportionately increased in hearts of aged rats compared
with younger rats (14). Our data are consistent with these
latter observations, as we did not observe an absolute
increase in MGU (corrected for MVO2) with age. However,
we observed that because MFAU declined with age and
MGU did not change, the proportional contribution of
glucose use to overall substrate utilization relative to fatty
acids was increased (Fig. 3).
Other potential causes for the metabolic shift. There are
many other determinants of the pattern of myocardial
substrate use. For example, myocardial fatty acid metabo-
lism is stimulated by increases in plasma fatty acid levels and
inhibited by increases in plasma insulin levels (11,12).
However, the age-related differences in myocardial fatty
acid metabolism we observed cannot be attributed to dif-
ferences in plasma fatty acid and insulin levels, as they were
comparable between the older and normal subjects (Table
1). Plasma lactate levels were slightly, but significantly,
higher in the older subjects, the cause of which is unclear.
However, this increase in plasma lactate levels did not
contribute to the decrease in MFAU and MFAO in the
older subjects (Fig. 4). This is consistent with the observa-
tion that marked increases in plasma lactate levels (typically
6 to 8 greater than the levels in the current study) are
necessary to suppress MFAU (28,29). That being said, we
cannot exclude that myocardial extraction of lactate in-
creased with age, which, in turn, would lead to an increase
in myocardial lactate utilization. It is also unlikely that the
age differences in fatty acid metabolism we observed were
attributable solely to the decline in beta-adrenergic sensi-
tivity that occurs with age (9,10). This is because, in general,
catecholamines lead to in an increase in glucose uptake,
oxidation, and glycogenolysis relative to fatty acid uptake
and oxidation (30). Thus, in the state of reduced beta-
adrenergic sensitivity, a relative decline in fatty acid metab-
olism should not have occurred. Increases in cardiac work
can preferentially increase MGU relative to MFAU and
MFAO (22). The systolic and diastolic blood pressures were
higher in the older subjects compared with the younger
subjects, which, as expected, was paralleled by a similar
increase in MVO2 in the older subjects. Consequently, we
corrected the metabolic measurements for the level of
MVO2.
The decline in MFAO and, thus, MFAU with age may
reflect alterations in mitochondrial lipid content, lipid
composition, and protein interactions as well as oxygen free
radical injury with subsequent lipid peroxidation of mito-
chondrial membranes leading to significant membrane dys-
function (31–33). Lastly, the decline in MFAU and MFAU
may reflect the metabolic effects of impaired myocardial
vasodilator capacity that occur with age (3,4).
Potential limitations. We did not show conclusively that
glucose supercedes fatty acids as the primary source for the
energy production by the myocardium in older humans even
though our results demonstrate that, with age, MFAU and
MFAO decrease, and MGU remains unchanged. This is
because current PET approaches only permit measurements
of overall myocardial glucose utilization and, thus, do not
provide any information regarding the metabolic fate of
extracted glucose. For example, if most of the extracted
glucose enters glycogen synthesis as opposed to glycolysis,
then little energy production would arise from extracted
glucose. However, the finding in experimental models of
aging that glycogen content decreases with age makes this
scenario less likely (34). Moreover, the current study design
could not delineate whether other exogenous substrates such
as lactate were being used in lieu of fatty acids in the older
subjects. In such a case, the relative proportion of glucose
metabolism to overall substrate metabolism might not
increase with age. Also, our current methods only permit us
to assess the uptake or metabolic fate of tracers of extract-
able substrates. The currently available methods do not
provide any insight into energy produced from endogenous
myocardial sources such as triglycerides and glycogen. Thus,
the contribution of triglyceride or glycogen breakdown as an
energy source is unknown.
Clinical implications of the metabolic shift. It remains to
be determined what are the clinical implications of this
age-related shift in myocardial substrate metabolism. For
example, the shift in myocardial substrate towards a lesser
dependence on fatty acid metabolism may render the
myocardium more resistant to ischemia, demonstrating a
beneficial effect. This may be of particular importance
because the incidence of coronary artery disease increases
with age. In contrast, this age-related metabolic shift may
have deleterious consequences. The age-related shift in
metabolism may accentuate the switch in substrate metab-
olism that occurs in both animal models and in humans with
pressure-overload-induced left ventricular hypertrophy and
in dilated cardiomyopathy.
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